Protective Assessment of Novel (Bncs Formulation) against Brain Tumor

Title:Protective Assessment of Novel (Bncs Formulation) against Brain Tumor

Volume: 19

Author(s): Anuradha Mishra*, Afza Ahmad, Irfan Ahmad Ansari and Rohit Kumar Tiwari*

Affiliation:

• Amity Institute of Pharmacy, Lucknow, Amity University Uttar Pradesh, Sector-125, Noida-201313, Uttar Pradesh, India

• Department of Clinical Research, Sharda School of Allied Health Sciences, Sharda University, Gautum Budh Nagar, Uttar Pradesh, 201310, India

Abstract: Background: Oxidative stress refers to non-homeostatic elevation within intracellular reactive oxygen species (ROS) levels and is associated with several neuro-related pathological conditions. Diclofenac is a commonly prescribed non-steroidal anti-inflammatory drug (NSAID) for treating aches and pain by reducing inflammation. Diclofenac is also associated with the induction of apoptotic cell death by altering the homeostatic balance within mitochondria. In the present report, the neuroprotective effects of BNC formulation constituted by Bacopa monnieri leaves, Nigella sativa and Curcuma longa rhizome seeds were investigated.

Methods: The synthesized formulation was characterized using FT-IR and LC-MS along with organoleptic evaluation. Thereafter neuroprotective efficacy of BNC formulation was subsequently investigated against Diclofenac-induced oxidative stress in SH-SY5Y cells. The cells were pretreated with synthesized formulation and subsequently evaluated for amelioration in Diclofenac-induced cytotoxicity, and ROS augmentation. The neuroprotective effect of synthesized formulation was further explored by evaluating the changes in nuclear morphology, and apoptosis alleviation with concomitant regulatory effects on caspase-3 and -9 activation.

Results: Diclofenac was found to be considerably cytotoxic against human neuroblastoma SHSY5Y cells. Intriguingly, Diclofenac-mediated toxicity was reduced significantly in SH-SY5Y cells pretreated with BNC formulation. Augmented ROS levels within Diclofenac-treated SHSY5Y cells were also reduced in the BNC formulation pretreated SH-SY5Y cells. Furthermore, BNC formulation pretreated SH-SY5Y cells also exhibited reduced dissipation of mitochondrial membrane potential, caspase-3 and -9, along with apoptosis after Diclofenac treatment.

Conclusion: These findings indicated that, indeed, Diclofenac induces considerable ROSmediated apoptosis in SH-SY5Y cells, which further intriguingly ameliorated Diclofenacmediated cytotoxic effects on SH-SY5Y cells. This manuscript further collected information about available National and International patents published or granted in preparation of and thereof applications against motor and non-motor brain dysfunctions.

Cite this article as:

Mishra Anuradha*, Ahmad Afza, Ansari Ahmad Irfan and Tiwari Kumar Rohit*, Protective Assessment of Novel (Bncs Formulation) against Brain Tumor, Recent Patents on Anti-Cancer Drug Discovery 2024; 19 () . https://dx.doi.org/10.2174/0115748928272753231212043701